n Cardiovascular Journal of South Africa - AstraZeneca's investment in landmark trials in heart failure : drug trends in cardiology




Extracted from text ... Heart failure is a common, distressing and disabling illness and is associated with a worse outcome than in many forms of cancer. For many patients, the prognosis is poor: it is estimated that 50% of patients with heart failure will die within five years. It is estimated that up to 50 million of the 1 000 million people (5%) who inhabit the 47 nations which are members of the European Society of Cardiology may have a heart failurerelated problem.1 It is also a severe burden on healthcare resources. The direct costs of heart failure in developed countries are thought to ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error